昭衍新药(06127.HK) 公布9月止首三季度业绩，按中国会计准则，实现营业收入13.35亿人民币(下同)，按年下降15.9%。录得亏损7,031万元，相较上年同期净利润3.28亿元，盈转亏，归因竞争加剧，销售收入及毛利率下降，以及生物资产公允价值下降；每股亏损9分。(de/d)(港股报价延迟最少十五分钟。)
| 公布日期 | 派息事项 | 派息内容 |
|---|---|---|
| 2024/08/30 | 中期业绩 | 无派息 |
| 2024/04/29 | 第一季业绩 | 无派息 |
| 2024/03/28 | 末期业绩 | 普通股息：人民币 0.16 (相当于港元 0.18) |
| 2023/10/30 | 第三季业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.